Evidence map›Paper›PMID 34248932›Full record

ArticleFrontiers in immunology2021

Immunoreactivity of Sera From Low to Moderate Malaria-Endemic Areas Against

Myriam Arévalo-Herrera, Kazutoyo Miura, Nora Cespedes, Carlos Echeverry, Eduardo Solano, Angélica Castellanos, Juan Sebastián Ramirez, Adolfo Miranda, Andrey V Kajava, Carole Long and 2 more

Expression of concernOpen access · goldAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Cross-reactivity of rbioRxiv : the preprint server for biology · 2024
    Article
  3. Article
  4. Review
  5. Frontiers in cellular and infection microbiology · 2022
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Myriam Arévalo-HerreraImmunology Department, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
Nora CespedesImmunology Department, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Carlos EcheverryImmunology Department, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Eduardo SolanoImmunology Department, Caucaseco Scientific Research Center, Cali, Colombia.
Angélica CastellanosImmunology Department, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Juan Sebastián RamirezImmunology Department, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Adolfo MirandaParasitology Department, Centro Nacional de Epidemiología (CNE), Guatemala City, Guatemala.
Andrey V KajavaCentre de Recherche en Biologie Cellulaire de Montpellier, Université Montpellier, Montpellier, France.
Carole LongLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
Giampietro CorradinBiochemistry Department, University of Lausanne, Epalinges, Switzerland.
Sócrates HerreraImmunology Department, Malaria Vaccine and Drug Development Center, Cali, Colombia.
Caucaseco Scientific Research Center · CODepartamento de Epidemiología · GTNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USUniversité de Montpellier · FRUniversity of Lausanne · CH

Funding

Host Immune Responses to Antigens of Malaria ParasitesZIAAI001020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, CAROLE · 2009 to 2025
$13.6M
Vector Biology Research and Integrated Vector Management For Malaria ControlU19AI089702 · NIAID · CAUCASECO SCIENTIFIC RESEARCH CENTER · PI QUINONES, MARTHA · 2010 to 2016
$11.5M
Plasmodium vivax 48/45 gametocyte protein: functional characterization and vaccine potential assessment in preclinical studiesR01AI121237 · NIAID · MALARIA VACCINE DEVELOPMENT CENTER · PI AREVALO-HERRERA, MYRIAM · 2016 to 2019
$1.6M
NIAID NIH HHS R01 AI121237NIAID NIH HHS U19 AI089702
6 · The paper itself

Abstract

P48/45 is a conserved gametocyte antigen involved in

Indexed as

Endemic DiseasesSerologic TestsAdolescentAdultAgedAged, 80 and overAnimalsAntibodies, ProtozoanAntibody SpecificityAntigens, ProtozoanChildCHO CellsColombiaCricetulusEscherichia coliFemaleAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GRecombinant ProteinsgametocytesmalariaPlasmodium vivaxPvs48/45transmission blockingvaccines

Identifiers

PMID34248932
PMCPMC8264144
OpenAlexW3174046596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.